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Summary Cytosols of human breast tumours have been assayed for DNA dependent DNA polymerase at
activity. DNA polymerase a activity in benign tumours was found to be significantly lower than in untreated
malignant tumours. Biopsy samples removed surgically before and after endocrine therapy showed reduced
DNA polymerase a activity in 6 out of 9 patients treated with 4-hydroxyandrostenedione, and in 6 out of 7
patients treated with MPA. DNA polymerase a activity in malignant breast tumours was higher in oestrogen
receptor negative than oestrogen receptor positive tumours.
Two DNA dependent DNA polymerases, DNA polymerase az
and 1, are found in the cell nucleus and are involved in the
synthesis of nuclear DNA (Hubscher, 1983). DNA poly-
merase a is associated with proliferating tissues (Lynch et al.,
1976) and tumours (DePhilip et al., 1977), and is elevated
during the late G, to mid S phase of the cell cycle, whereas
the activity of DNA polymerase P remains unchanged (Chiu
& Baril, 1975; Barr et al., 1975). In vivo, the activity of DNA
polymerase a has been correlated with cellular proliferation
in a variety of steroid hormone target tissues including the
rat ventral prostate gland (Rennie et al., 1975) and the rat
uterus (Harris & Gorski, 1978). DNA polymerase is tightly
bound to the nucleus whereas DNA polymerase a is lightly
bound and extracted under aqueous conditions (Foster &
Gurney, 1976; Edwards et al., 1980).
We have assessed breast tumour proliferation by measur-
ing the activity of DNA polymerase ox in malignant and
benign tumours, and in malignant tumours before and after
endocrine therapy with either the aromatase inhibitor 4-
hydroxyandrostenedione (4-OH A) or with the synthetic pro-
gestogen medroxyprogesterone acetate (MPA). In untreated
malignant breast tumours correlations of DNA polymerase a
activity with oestrogen receptor binding and tumour size are
reported.
Patients and methods
Patients
Breast tumour samples were obtained from 30 women with
untreated malignant tumours and 16 women with benign
tumours. Biopsy samples were removed from patients with
malignant breast tumours before and after treatment with
either MPA (500 mg day ' for 2 weeks intramuscularly) or
4-OH A (500 mg on day I of treatment and 500 mg on day
11, intramuscularly). All of the patients in this study were at
least one year postmenopausal except for one patient treated
with MPA who was perimenopausal. Two patients treated
with 4-OH A and three patients treated with MPA had
previously been treated with tamoxifen. The patients treated
with 4-OH A and MPA had stages 3 and 4 breast cancer.
Analytical methods
Tumour samples were removed at surgery, divided into two
pieces, and snap frozen in liquid nitrogen. One sample was
used to assay DNA polymerase a activity the other to assay
oestrogen receptor binding. The tumour diameter was
recorded pathologically after surgical removal with a ruler.
Tissue samples (approximately 250 mg) were homogenised
in 2.5 ml buffer (10 mM Tris-HCl:3 mM MgCI2:2 mM
dithiothreitol, pH 7.8) using a Polytron electric homogeniser.
The homogenate was centrifuged for 10 minutes at 800 g and
the nuclear supernatant retained. The nuclear pellet was
washed again in buffer and the supernatants combined. The
pooled supernatant was centrifuged at 105,000 g in a Beck-
man spinco ultracentrifuge for 1 hour at 4°C, and the cytosol
was retained. An aliquot of the cytosol was saved for protein
determination (Lowry et al., 1951).
Assay ofDNA polymerase a activity
DNA polymerase ax activity was determined as has been
described previously (Edwards et al., 1980) using the incor-
poration of 3H-thymidine triphosphate (TTP) into an acid
insoluble product with activated calf thymus DNA as a
template primer (Aposhian & Kornberg, 1962). In brief,
100 1l of tumour cytosol was added to 300gld containing
50mM Tris (pH7.4), 2.5mM dithiothreitol, 10mM MgCl2,
2 mM adenosine triphosphate, 0.2 mM deoxyadenosine tri-
phosphate, deoxycytosine triphosphate and deoxyguanosine
triphosphate, 80 tiM TTP, 1 I[Ci 3H-TTP and 250 Lg activated
calf thymus DNA. After one hour the reaction was stopped
by adding 22 ml 10% trichloroacetic acid (TCA) containing
1% sodium pyrophosphate. The acid insoluble product was
collected on Whatman membrane filters (0.45itm diameter
pore size) and then washed with a further 20 ml 5% TCA
containing 1% sodium pyrophosphate. The filters were
counted with 10ml of scintillation cocktail (Packard filter
count). Samples were assayed in duplicate, and blank tubes
(reaction stopped at time zero) were subtracted from the
sample tubes. The coefficient of variation between duplicate
assay tubes was 8%.
Under these conditions enzyme activity was linear with
time for up to 2 hours and linear with protein concentration
(1-5mg of protein ml-').
The DNA polymerase a activity is expressed as pmols TTP
incorporated per hour per mg cytosolic protein.
Oestradiol receptor assay
Malignant breast tumour samples were dispatched frozen on
dry ice to the Tenovus Institute for Cancer Research, Cardiff,
for assay of oestrogen receptor binding by the dextran-
charcoal method (Nicholson et al., 1979).
Statistical calculations
The DNA polymerase a activity was log normalised, and
therefore statistical analyses were performed with log trans-
formed data. Arithmetic means and standard deviations are
quoted. The Student's and paired t tests were used for
significance testing where appropriate. A least squares linear
regression was employed for correlation testing.
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Results
400 Breast tumour DNA polymerase
A cytosol preparation from a malignant breast tumour gave
optimal enzyme activity at pH 7.4 and was absolutely depen-
dent on the presence of magnesium ions showing optimal
activity between 2.5 to 5 mM Mg2' at pH 8. Fifteen breast
tumour (malignant and benign) cytosols were tested and
found to be 90-95% inhibited by the sulphydryl reagent
N-ethyl-maleimide (5 mM). Sensitivity was also observed to
KCI and cytosine-B-D-arabinofuranoside 5'-triphosphate.
These features are characteristic of DNA polymerase a
(Hubscher, 1983; Niedbalski et al., 1986; Edwards et al.,
1980).
DNA polymerase a in malignant and benign breast tumours
The specific activity of DNA polymerase a (data not log
transformed) in 30 breast carcinomas and 16 benign breast
tumours is illustrated in Figure 1. The mean activity ± s.d.
(pmol TTP incorporated h-' mg protein-') in malignant
tumours was 177 ± 120 and in benign tumours 21 ± 26. The
specific activity of DNA polymerase a was significantly
elevated in malignant tumours (P <0.0001). The pathology
of the benign tumours consisted of: 12 cases of benign mam-
mary dysplasia, one involuted fibroadenoma, one case of
fibrocystic disease and two cases of adenosis with epitheliosis
and fibrosis.
DNA polymerase a activity in malignant tumour biopsy
samples before and after endocrine therapy with either 4-OHA
or MPA
Tumour biopsy samples were obtained, before and after
treatment, from 9 patients treated with 4-OH A and from 7
patients treated with MPA. The specific activity of DNA
polymerase x before and after treatment with either 4-OH A
or MPA is shown in Figure 2. The mean ± s.d. activity of
DNA polymerase a (pmol TTP incorporated h-' mg pro-
tein-') was not significantly changed before (94 56) com-
pared with after (66 ± 43) treatment with 4-OH A. DNA
polymerase a activity was reduced in 5 patients, increased in
one patient and unchanged in 2 patients following treatment
with 4-OH A. A significant (P <0.025) reduction in
mean ± s.d. DNA polymerase a activity from 305 ± 150 to
176 ± 110 was found following treatment with MPA. Six
patients showed a decrease and one patient an increase in
DNA polymerase a activity after treatment with MPA. The
average reduction in DNA polymerase a was 30% after
treatment with 4-OH A and 43% after treatment with MPA.
A change in DNA polymerase x activity after treatment
compared with before treatment of greater than 8% (the
within batch coefficient of variation) was regarded as a
significant change for individual patients.
DNA polymerase a activity in malignant tumours and
correlations with oestrogen receptor binding and tumour size
Sixty-seven per cent of the tumours were oestrogen receptor
positive (binding of more than 10 fmol ligand mg protein-')
with a mean binding of 91 fmol mg protein-'. The
mean ± s.d. DNA polymerase a activity (pmol TTP incor-
porated h-' mg protein-') was significantly (P <0.05) higher
in oestrogen receptor negative tumours (233 ± 107) than in
oestrogen receptor positive tumours (148 ± 119). No
significant correlation between DNA polymerase a activity
and oestrogen receptor binding (r = - 0.25) was observed.
No significant correlation between DNA polymerase a
activity and malignant tumour size was observed (r = 0.27).
The average tumour diameter was 2.5 cm.
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Figure 1 DNA polymerase a activity in M (malignant) tumours
and in B (Benign) tumours.
Discussion
We have observed a significantly lower specific activity of
DNA polymerase a in benign breast tumours compared with
untreated malignant breast tumours suggesting that cellular
proliferation in benign tumours was reduced. Some benign
tumours were quiescent with no detectable DNA polymerase
a activity while the DNA polymerase a activity in other
benign tumours overlapped with that of some tumours in the
malignant tumour group. Other techniques of assessing cel-
lular proliferation have also shown a lower rate of prolifera-
tion in benign than in malignant breast tumours (Kute et al.,
1981; Sincock, 1986).
The mean specific activity of DNA polymerase a was
significantly reduced in the biopsy samples removed from
patients after treatment with MPA compared with before
treatment. Six of the seven patients treated with MPA
showed reduced DNA polymerase a activity after treatment.
Although the mean specific activity of DNA polymerase a
was not significantly reduced following treatment with 4-
OH A, six of the nine patients showed a reduction in DNA
polymerase a activity after treatment. The measurement of
DNA polymerase a activity in biopsy samples before and
after endocrine therapy provides information concerning the
response to this therapy of individual patients. Although
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Figure 2 a, DNA polymerase ax activity before and after treat-
ment with 4-OH A. DNA polymerase ax activity before treatment
vs after treatment no significant change (by paired t test). b,
DNA polymerase oa activity before and after treatment with
MPA. DNA polymerase ax activity before treatment vs after
treatment (P <0.025). *Indicates patients previously treated with
tamoxifen.
there may be no statistically significant change in mean DNA
polymerase a activity before therapy compared with after,
individual patients may show large changes. Clinical response
rates to different endocrine therapies such 4-OH A and MPA
are typically 30-40% (Harmsen & Porsius, 1988).
A 4-OH A is thought to exert its antiproliferative action by
causing a reduction in oestrogen production. Competitive
inhibition of aromatase activity in human placental micro-
somes and tumour regression of hormone dependent car-
cinogen induced rat tumours following 4-OH A has been
demonstrated (Brodie et al., 1983). In postmenopausal
women a single injection of4-OH A (500 mg i.m.) suppressed
serum oestradiol to an average of 36% of the base line after
4-7 days (Dowsett et al., 1987).
High dose MPA (>500 mgday-') has been used with
some success in the treatment of breast cancer (Izuo et al.,
1981) and with other therapies (Ghilchik et al., 1987). In vitro
MPA has been shown to have an antiproliferative action on
breast cancer cell growth and this was accompanied by a
reduction in DNA polymerase a activity (Purohit et al.,
1990). The growth inhibitory action of MPA is thought to be
mediated through the progestogen receptor (Horwitz et al.,
1985), but interactions of MPA with other steroid receptors
have been reported (Teulings et al., 1980; Poulin et al., 1989).
We found no significant correlation between oestrogen
receptor binding and DNA polymerase a activity in un-
treated malignant tumours. A negative correlation between
malignant breast tumour cell proliferation and oestrogen
receptor binding has been reported (Meyer et al., 1986) but
the correlation was of a low order. We did observe a
significantly higher activity of DNA polymerase a activity in
oestrogen receptor negative than oestrogen receptor positive
malignant breast tumours. A higher rate of breast tumour
proliferation, assessed by flow cytometry, has been found in
oestrogen receptor negative than oestrogen receptor positive
tumours (Kute et al., 1981). No significant relationship
between tumour size and DNA polymerase a was found in
our study, however, a weak positive correlation between
breast tumour size and tumour cell proliferation has been
observed (Meyer et al., 1986).
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